Aligos Therapeutics announces $8.5 million contract award to NIAID to advance development of first-in-class pan-coronavirus protease inhibitor ALG-097558

Aligos Therapy

Aligos Therapy

– NIAID contract will support nonclinical and clinical studies to advance ALG-097558 into future Phase 2/3 studies

– This is the second NIH grant to advance the development of ALG-097558

– First human Phase 1 study evaluating single/multiple doses of ALG-097558 in healthy volunteers ongoing

– Aligos plans to continue to seek external funding to advance ALG-097558 beyond ongoing Phase 1 human studies

SOUTH SAN FRANCISCO, Calif., Oct. 03, 2023 (GLOBE NEWSWIRE) — Aligos Therapeutics, Inc. (Nasdaq: ALGS) is a clinical-stage biopharmaceutical company focused on developing novel therapies to treat liver and , a company with unmet medical needs in viral diseases, announced today that it has been awarded an $8.5 million contract from the National Institute of Allergy and Infectious Diseases (NIAID) to conduct nonclinical and clinical studies to develop its pan-coronavirus Protease inhibitor ALG-097558 advanced to future Phase 2/3 study.

“We are honored to receive this NIAID contract, our second to develop novel coronavirus 3CL protease inhibitors,” said Lawrence Blatt, PhD, MBA, chairman and CEO of Aligos Therapeutics. NIH funding for agents.” “Given that ALG-097558 is effective against all forms of coronaviruses tested to date (SARS-CoV, MERS-CoV, SARS-CoV-2, and seasonal coronaviruses), we believe this compound will be effective against the ongoing COVID-19 pandemic Very important as well as future treatments for emerging novel coronavirus infections in humans. These non-dilutive external funds will allow Aligos to continue advancing the ALG-097558 program beyond the ongoing Phase 1 study, which is evaluating healthy volunteers. Single dose and multiple doses.”

About ALG-097558

ALG-097558, a potent small molecule inhibitor of the pan-coronavirus 3CL protease, is currently being evaluated in an ongoing first-in-human study (NCT05840952) in healthy volunteers. The project is part of a collaboration and licensing agreement with KU Leuven, which includes its Center for Drug Design and Discovery (CD3), KU Leuven’s drug discovery arm and investment fund, and the Rega Medical Research Institute. ALG-097558 has been pharmacologically optimized to have favorable drug interaction profiles and a higher resistance barrier compared to other PIs in development. Preclinical activities in the ALG-097558 program are funded in part by a grant from the National Institutes of Health (NIH) and NIAID’s Antiviral Drug Discovery (AViDD) Epidemic Pathogens Center through the Metropolitan Antiviral Drug Accelerator (MAVDA) consortium. The ALG-097558 program is also currently receiving federal funding from the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, and the Department of Health and Human Services under Contract No. 75N93023C00052, which will partially support further clinical development of the drug. ALG-097558.

About Arrigos

Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded in 2018 with a mission to become a world leader in the treatment of liver and viral diseases. Aligos’ strategy is to leverage its team’s deep expertise and decades of drug development experience in liver and viral diseases to discover and develop drugs targeting non-alcoholic steatohepatitis (NASH) and viruses with high unmet medical need, such as potential best treatments for coronaviruses and chronic viruses). Hepatitis B (CHB).

forward-looking statements

This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be deemed “forward-looking statements,” including, but not limited to, Aligos’ belief that the compound is useful for the ongoing pandemic of COVID-19 and for the treatment of possible future novel coronaviruses from animals to humans. viral species are important; these non-dilutive external funds will allow Aligos to continue advancing the ALG-097558 program beyond the ongoing Phase 1 study; Aligos plans to continue to seek external funding to advance ALG-097558 beyond the ongoing Phase 1 study Phase human studies. Forward-looking statements are often, but not always, identified by the use of words such as “may,” “will,” “would,” “believe,” “intend,” “plan,” “anticipate,” “estimate” and other similar words. “Expectations” and other similar terms referring to future results. Such forward-looking statements are subject to significant risks and uncertainties that could cause our development plans, future results, performance or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include, but are not limited to, those inherent in the drug development process, including Aligos’ clinical development stages, the process of designing and conducting clinical trials, the regulatory approval process, the timing of regulatory filings, challenges and manufacturing pharmaceutical-related matters, Aligos’ ability to successfully establish, protect and defend its intellectual property rights, other matters that may affect the sufficiency of Aligos’ capital resources to fund operations, reliance on third parties for manufacturing and development efforts, and the competitive landscape. Relevant information that may result in For a further description of the risks and uncertainties that actual results may differ from those anticipated in these forward-looking statements, as well as the risks associated with Aligos’ business in general, please see Aligos’ Quarterly Report on Form 10-Q filed with U.S. Securities and Exchange Commission on August 3, 2023 Reports filed with the Exchange Commission and future periodic reports to be filed or filed with the Securities and Exchange Commission. Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events, except as required by law.

Media Contact
Veronica Eames
Life Sciences Newsletter
+1 646 970 4682

Investor Contact
Dr. Corey Davis
life sciences consultant
+1 212 915 2577

Source link

Leave a Comment